AnneMarie Wenthzel - Sprint Bioscience Director of Sales and Marketing
| SPRINT Stock | SEK 1.75 0.01 0.57% |
Director
Ms. AnneMarie Wenthzel serves as Head of Business Development at Sprint Bioscience AB. She was employed at the Company since 2011. She holds a degree in Microbiology from Stockholms universitet. She has experience as Researcher in Internal Medicine from Sahlgrenska Universitetssjukhuset, Product Specialist at AH Diagnostics och Stratagene, Key Account Manager at PerkinElmer, CEO Miterovia AB . She has a background as a researcher in type 2 diabetes. Since 2003, she has worked in sales and marketing of life science as well as running her own business.
| Age | 59 |
| Phone | 46 84 11 44 55 |
| Web | https://www.sprintbioscience.com |
Sprint Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.5879) % which means that it has lost $0.5879 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0926) %, meaning that it generated substantial loss on money invested by shareholders. Sprint Bioscience's management efficiency ratios could be used to measure how well Sprint Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Karin Leandersson | Cantargia AB | 43 | |
| Patricia Delaite | Cantargia AB | 53 | |
| Thoas Fioretos | Cantargia AB | 53 | |
| Claus Andersson | Cantargia AB | 51 | |
| Anders MartinLof | Cantargia AB | 48 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 |
Sprint Bioscience Leadership Team
Elected by the shareholders, the Sprint Bioscience's board of directors comprises two types of representatives: Sprint Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sprint. The board's role is to monitor Sprint Bioscience's management team and ensure that shareholders' interests are well served. Sprint Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sprint Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AnneMarie Wenthzel, Director of Sales and Marketing | ||
| Martin Andersson, Founder and Director of Discovery Projects | ||
| Pr Nordlund, Founder and Director | ||
| Jessica MSc, Founder, Director of Medicinal Chemistry and Director | ||
| Mathias Skalmstad, Chief Officer | ||
| Kenth Hallberg, Founder and Director of Structural Chemistry | ||
| Prof MBA, Chief Officer |
Sprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sprint Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (76.00) % | |||
| Current Valuation | 24.98 M | |||
| Shares Outstanding | 69.8 M | |||
| Shares Owned By Insiders | 35.31 % | |||
| Shares Owned By Institutions | 2.59 % | |||
| Price To Earning | 32.79 X | |||
| Price To Book | 2.61 X | |||
| Price To Sales | 27.09 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Sprint Stock
Sprint Bioscience financial ratios help investors to determine whether Sprint Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sprint with respect to the benefits of owning Sprint Bioscience security.